Você procurou por: tocilizumab (Maltês - Inglês)

roactemra 162 mg injezzjoni tocilizumab
roactemra 162 mg injection tocilizumab

kunjett fih 200 mg ta’ tocilizumab.
1 vial contains 200 mg tocilizumab.

1p<0.0001, tocilizumab kontra placebo
1p<0.0001, tocilizumab vs. placebo

- is- sustanza attiva hi tocilizumab.
- the active substance is tocilizumab.

tocilizumab kontra adalimumab bħala monoterapija
tocilizumab versus adalimumab in monotherapy

roactemra 20 mg/ml konċentrat sterili tocilizumab
roactemra 20 mg/ml sterile concentrate tocilizumab

kull ml ta’ konċentrat fih 20 mg tocilizumab*.
each ml concentrate contains 20 mg tocilizumab*.

roactemra 20 mg/ ml konċentrat sterili tocilizumab iv
roactemra 20 mg/ml sterile concentrate tocilizumab iv

siringa mimlija għal-lest waħda fiha 162 mg tocilizumab
1 pre-filled syringe contains 162 mg tocilizumab

tocilizumab jinnormalizza l-espressjoni ta’ dawn l-enżimi.
tocilizumab normalises expression of these enzymes.

tcz = tocilizumab a = skont il-popolazzjoni tal-protokoll
tcz = tocilizumab a = per protocol population

roactemra 20 mg/ml konċentrat għal soluzzjoni għall-infużjoni tocilizumab
roactemra 20 mg/ml concentrate for solution for infusion tocilizumab

is- sustanza attiva f’ roactemra, tocilizumab, hija antikorp monoklonali.
the active substance in roactemra, tocilizumab, is a monoclonal antibody.

kull kunjett ta’ 10 ml fih 200 mg tocilizumab (20 mg/ml).
each 10 ml vial contains 200 mg tocilizumab (20 mg/ml).

linearità il- parametri farmakokinetiċi ta ’ tocilizumab ma nbidlux maż- żmien.
linearity pharmacokinetic parameters of tocilizumab did not change with time.

0.26 avveniment għal kull 100 sena ta’ pazjent b’terapija ta’ tocilizumab.
0.26 events per 100 patient years with tocilizumab therapy.

fi studju i, tocilizumab ingħata minn ġol-vina kull erba’ ġimgħat bħala monoterapija.
in study i, tocilizumab was administered intravenously every four weeks as monotherapy.

il-profil globali ta’ avvenimenti avversi kliniċi kien simili bejn tocilizumab u adalimumab.
the overall clinical adverse event profile was similar between tocilizumab and adalimumab.

kull kunjett fih 200 mg ta’ tocilizumab* f’10 ml (20 mg/ml).
each vial contains 200 mg of tocilizumab* in 10 ml (20 mg/ml).

tqala m’ hemmx tagħrif biżżejjed dwar l- użu ta ’ tocilizumab waqt it- tqala.
pregnancy there are no adequate data from the use of tocilizumab in pregnant women.